If you spend any time in the GLP-1 research space, you have seen the muscle loss conversation. It is everywhere - in the community forums, in the medical press, in headlines about “Ozempic butt” and the fear that these drugs strip lean mass along with fat.
It is also a question people genuinely care about, because the whole point of body composition research is that losing fat is good and losing muscle is not. So what does the evidence actually say? Is muscle loss a real, measurable problem with GLP-1 drugs, or is it overstated?
The short answer is: there is a real signal, it is more nuanced than the scare headlines suggest, and the science is still settling it. Here is what we can actually say from the published research.
What the Data Shows: Fat Loss Dominates
The most important finding from the larger studies is that GLP-1 driven weight loss is mostly fat loss. When people lose weight on these drugs, the majority of what they lose is fat, not muscle.
A systematic review and meta-analysis published in the International Journal of Obesity (IJO) pulled together the body-composition data across trials of GLP-1 receptor agonists and examined how much of the weight loss was fat versus lean mass relative to the total lost. The pattern that emerged across studies is that fat loss accounts for the large majority of total weight lost, with lean mass making up a smaller fraction - consistent with what is generally seen in any significant weight loss, whether or not a drug is involved.
This is a useful baseline. It challenges the idea that GLP-1s are uniquely destructive to muscle. The proportionate lean loss seen on these drugs is broadly in line with what happens with substantial weight loss by other means.
The Nuance: It’s a Proportion, Not a Number
Where the conversation gets more interesting is the detail. The relevant question is not just “how much muscle do you lose,” but “how much muscle do you lose relative to how much you should, and does the drug matter?”
Here the research splits in an important way. In June 2026, a randomised controlled trial published in Nature tested apitegromab, a drug that blocks myostatin (a protein that limits muscle growth), in combination with tirzepatide. The trial showed that adding the anti-myostatin agent preserved lean mass during tirzepatide-induced weight loss. That is direct evidence that additional lean mass loss during GLP-1 treatment can be actively prevented - and that the body composition outcome depends on more than just the weight-loss drug itself.
Separately, real-world data added a layer. A medRxiv analysis using body-composition “digital phenotyping” in routine care found greater lean-body-mass decline with tirzepatide than with semaglutide. That specific comparison - Mounjaro losing more lean mass than Ozempic - became the basis for a wave of coverage, including from EMJ and Healthline, that framed semaglutide as “preserving muscle better” than tirzepatide.
None of this settles the question cleanly. What it does do is reframe it. The evidence is not “GLP-1s destroy muscle.” It is “weight loss includes some lean mass loss, which is mostly fat, and the amount of lean loss can vary between drugs and can be influenced by other interventions.”
The Two Stories Getting Mixed Up
A lot of the confusion comes from two different stories being told as one.
The first is the broad question of whether GLP-1 drugs cause problematic muscle loss. The answer, on the evidence, is largely no - the lean loss is a normal proportion of weight loss, and it is mostly fat coming off. Coverage from News-Medical (“GLP-1 weight loss is driven mainly by fat loss, not muscle loss”) and the Lifespan Research Institute (“GLP-1 drugs’ muscle effects similar to ordinary weight loss”) reflects that framing.
The second is the specific, science-y debate about whether some drugs in the class lose more lean mass than others, and whether you can stack something on top to preserve muscle. That is where the tirzepatide-versus-semaglutide data, the myostatin work, and the growing interest in combination approaches live. This second story is real, active, and genuinely interesting - but it is not the same as “GLP-1s waste your muscle away.”
Why the Community Cares
For a research community, this distinction matters more than it does to the general public. People tracking body composition on these compounds tend to be measuring themselves - watching lean mass, protein intake, training load and how their body responds.
The research interest here is practical. If you are losing weight and you want to preserve as much lean tissue as possible, the evidence points to the things you would expect to matter: the rate of weight loss, how much muscle you have going in, protein intake, resistance training, and no large additional losses on top. The myostatin work is early and nowhere near clinical use, but it points at a future where body composition during weight loss is treated as a target in its own right.
There is also a genuine open question that honest coverage should flag. The long-term metabolic consequences of any lean mass lost during GLP-1 treatment are still being worked out. Muscle is metabolically active tissue, and questions about what happens if people lose and then regain - “rebound” - are not fully answered. Most of the media debate skips this, but it is the kind of uncertainty a research-minded audience should want to track.
What the Research Says
To summarise what we can actually assert from the published work:
- GLP-1 driven weight loss is mostly fat loss; the lean muscle component is a small fraction of total weight lost, generally in line with ordinary significant weight loss.
- Lean mass outcomes can differ between drugs in the class - real-world data suggests tirzepatide is associated with greater lean-body-mass decline than semaglutide, though this needs more confirmation.
- Lean mass loss during GLP-1 treatment can be reduced or prevented with additional interventions, as shown by the Phase 2 myostatin (apitegromab) trial combined with tirzepatide.
- The long-term implications of the lean mass component - including through regain cycles - remain an active area of research.
This is one of the healthiest debates in the GLP-1 space because it is actually resolvable with data, and the data is arriving. It deserves better than a scare headline on either side.
For compound-specific background, see our pages on semaglutide and tirzepatide, and join the conversation in the Grey Highway Telegram community.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources:
- Nature (June 8, 2026) - “Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial”
- International Journal of Obesity, Nature (April 25, 2026) - “GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity… a systematic review and meta-analysis”
- medRxiv (April 13, 2026) - “Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping”
- Medscape (July 24, 2026) - “Should We Be Concerned About Muscle Loss With GLP-1s?”
- MedPage Today (August 11, 2026) - “Ozempic Teeth, Muscle Loss: Some of the Buzziest GLP-1 Side Effects”
- News-Medical (April 27, 2026) - “GLP-1 weight loss is driven mainly by fat loss, not muscle loss”
- Lifespan Research Institute (May 12, 2026) - “GLP-1 Drugs’ Muscle Effects Similar to Ordinary Weight Loss”
- BBC (June 8, 2026) - “New drug to stop ‘Ozempic butt’ muscle loss side effect of obesity jabs”